Lupin falls 7% post Q1 results, hits over three month low

The pharmaceutical company reported a disappointing April-June quarter (Q1FY22) performance on the margins front

Shares of Lupin dipped 7 per cent to Rs 1,035.65, hitting an over three month low on the BSE in intra-day trade on Wednesday after the pharmaceutical company reported a disappointing performance for the April-June quarter (Q1FY22) on the margins front. The company's revenues, meanwhile, were driven by US$50 million licensing income and strong domestic growth. The stock was trading at its lowest level since April 19, 2021.

At 01:44 pm, Lupin was trading 6 per cent lower at Rs 1,051, as compared to a 0.14 per cent decline in the S&P BSE Sensex. The trading volumes on the counter